Cystic Fibrosis (CF) is a chronic lung disease that affects multiple organs, but the major cause of morbidity and mortality is the progressive remodeling of the airways, mucus accumulation, and chronic inflammation in the lung.
Palliative therapies have increased the life expectancy of CF patients, but recent advances in Regenerative CF Therapy particularly outside the United States and Canada have become a far more plausible therapy option for CF lung disease.
ICCA Global's next-generation Regenerative CF Therapy uses a cutting-edge cellular approach (via simple Intravenous Infusion) which is far less invasive than a complicated surgical lung transplant if even available.
ICCA Global's Regenerative CF Therapy is not yet available in the United States or Canada.
Clinical practice has shown that Regenerative CF Therapy can provide significant relief for CF lung disease by attenuating pulmonary inflammation while decreasing bacterial growth and enhancing antibiotic efficacy, and equally important, help the body secrete natural antibiotics such as LL-37 shown to reduce CF-associated infections.
There is no clinical evidence of dose-limiting toxicities, deaths, or other life-threatening adverse events caused by administering ICCA Global’s Regenerative CF Therapy to CF lung disease patients. Those few adverse events and serious adverse events that did occur were consistent with the underlying CF lung disease itself.
It is important to note that Regenerative CF Therapy is still a relatively new approach to treating CF, and more research is needed to determine its long-term efficacy and safety. However, the initial results are promising, and Regenerative CF Therapy has the potential to become a game-changer in the therapy of CF lung disease.
We are ready to help anytime. Let's talk about restoring your life!
Due to CF’s genetic nature, there is no cure for the disease using conventional standards of care, with current treatments limited to treating the symptoms, not the cause. CF lung disease and chronic autosomal recessive diseases are currently treated with by following:
Regenerative Therapy offers patients a viable alternative treatment to conventional “standard of care” medicine. Clinical evidence shows that ICCA’s Regenerative CF Therapy has the potential to treat the disease and restore healthy lung function.
Regenerative CF Therapy helps CF patients in several ways, including:
Pulmonary rehabilitation is highly recommended after any treatment. Pulmonary rehabilitation can also be beneficial for patients having severe difficulty breathing or severe hardening of the lungs.
Important: Regenerative CF Therapy may not be appropriate for all CF lung patients. Those with multiple conditions, very late stage, or travel restrictions due to the need for constant oxygen may not qualify for the 3-day treatment protocol.
Loss of cystic fibrosis regulator gene function can affect multiple organs including the pancreas, lungs, liver, kidney, and intestines. Due to varying degrees of severity and stages, our pulmonary specialists will need to understand the patient’s current medical needs to qualify any potential candidates for treatment. Our initial review can be easily done online.
Our team is ready to help you get your life back! Please enter your contact information and a Patient Navigator will contact you shortly.